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Abstract
Background: Many myopathies share clinical features in common, and diagnosis often requires genetic testing.
We ascertained a family in which five siblings presented with distal muscle weakness of unknown etiology.
Methods: We performed high-density genomewide linkage analysis and mutation screening of candidate genes to
identify the genetic defect in the family. Preserved clinical biopsy material was reviewed to confirm the diagnosis,
and reverse transcriptase PCR was used to determine the molecular effect of a splice site mutation.
Results: The linkage scan excluded the majority of known myopathy genes, but one linkage peak included the
gene GNE, in which mutations cause autosomal recessive hereditary inclusion body myopathy type 2 (HIBM2).
Muscle biopsy tissue from a patient showed myopathic features, including small basophilic fibers with vacuoles.
Sequence analysis of GNE revealed affected individuals were compound heterozygous for a novel mutation in the
5’ splice donor site of intron 10 (c.1816+5G>A) and a previously reported missense mutation (c.2086G>A, p.V696M),
confirming the diagnosis as HIBM2. The splice site mutation correlated with exclusion of exon 10 from the
transcript, which is predicted to produce an in-frame deletion (p.G545_D605del) of 61 amino acids in the kinase
domain of the GNE protein. The father of the proband was heterozygous for the splice site mutation and exhibited
mild distal weakness late in life.
Conclusions: Our study expands on the extensive allelic heterogeneity of HIBM2 and demonstrates the value of
linkage analysis in resolving ambiguous clinical findings to achieve a molecular diagnosis.
Background
Hereditary inclusion body myopathy (HIBM) is charac-
terized by slowly progressive muscle weakness, preferen-
tially affecting the tibialis anterior and usually sparing
the quadriceps. Onset is generally between the ages of
20 and 40 and serum creatine kinase (CK) levels are
normal or minimally elevated. Histological features
include the presence in myofibers of vacuoles rimmed
with basophilic granular material, as well as cytoplasmic
filamentous inclusions on electron microscopy [1].
Rimmed vacuoles are a defining characteristic of HIBM,
but are also observed less consistently in other muscle
disorders [2], including limb girdle muscular dystrophy
(LGMD) types 1A [3] and 2G [4]. The autosomal reces-
sive HIBM type 2 (HIBM2) is caused by mutations in
t h eg e n ee n c o d i n gg l u c o s a m i n e( U D P - N-acetyl)-2-epi-
merase/N-acetylmannosamine kinase (GNE)[ 5 ] ,a n di s
allelic with distal myopathy with rimmed vacuoles
(DMRV), also known as Nonaka myopathy (NM) [6-10].
We present a family with multiple siblings affected
with a distal myopathy with vacuolated myofibers. Link-
age analysis excluded known genes for recessive forms
of LGMD and many other muscle disorders, but direc-
ted our attention to GNE as a likely candidate. The
identification of compound heterozygous mutations in
GNE, including a novel splice site mutation, confirmed
the diagnosis as HIBM2.
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Written informed consent for participation in this study
was obtained for all subjects, in accordance with the
Institutional Review Board of Children’sH o s p i t a lB o s -
ton. Patient confidentiality was protected in accordance
with the Health Insurance Portability and Accountability
Act of 1996. Saliva samples were collected using the
Oragene·DNA kit (DNA Genotek) and genomic DNA
was isolated. Seven family members were genotyped at
10,204 single nucleotide polymorphisms using the Gene-
Chip Human Mapping 10 K 2.0 Xba Array (Affymetrix).
Genomewide multipoint parametric linkage scans were
performed using MERLIN v1.1.2 [11]. The disease allele
frequency was set to 0.0001 and we used a full pene-
trance, zero phenocopy model. Marker map positions
and Caucasian allele frequencies were provided by Affy-
metrix. The error checking and Pedwipe functions of
MERLIN were used to remove unlikely genotypes.
Amplification of candidate gene exons and splice junc-
tions by polymerase chain reaction (PCR) and sequen-
cing of purified products were performed by standard
p r o t o c o l s ,a n ds e q u e n c ed a t aw e r ea n a l y z e du s i n g
Sequencher v4.8 (Gene Codes) and SeqScape v2.5
(Applied Biosystems). The c.1816+5G>A mutation was
genotyped in DNA samples from unrelated control sub-
jects using a Custom TaqMan SNP Genotyping Assay
(Applied Biosystems). Multi-species sequence alignments
were performed in ClustalW [12]. Mutation positions
were numbered relative to RefSeq transcript
NM_005476.5 and isoform NP_005467.1.
Muscle biopsy tissue was available for the proband,
and total RNA was isolated using the RNeasy Fibrous
Tissue Mini Kit (Qiagen). Additional saliva samples
were collected from the proband’s parents using the
Oragene·RNA kit (DNA Genotek) and total RNA was
isolated using the RNeasy Mini kit (Qiagen). The c.1816
+5G>A splice site mutation was characterized by reverse
transcriptase PCR (RT-PCR) using the SuperScript III
One-Step RT-PCR System (Invitrogen) and primers
designed to amplify exons 7 through 12. RT-PCR pro-
ducts were screened by the QIAxcel automated capillary
electrophoresis system (Qiagen). Selected products were
subjected to agarose gel electrophoresis and individual
bands were excised, gel-purified using the QIAquick Gel
Extraction Kit (Qiagen), and sequenced.
Results
Case reports
The family consisted of five affected siblings, two unaf-
fected siblings, their unaffected mother, and their father,
who had mild distal weakness noted late in life (Figure
1). The female proband presented at age 37 with weak-
ness, fatigue while walking, and difficulty walking and
climbing stairs. Her weakness was predominantly in the
distal lower extremities, which showed mild atrophy. She
exhibited quadriceps sparing, as knee extension strength
was 5/5 bilaterally on the Medical Research Council
scale, while knee flexion and hip flexion strength were 2/
5 bilaterally. Ankle dorsiflexion and eversion were 1/5 on
the right side and 0/5 on the left. The distal upper extre-
mities were less severely affected. Electromyography data
were unavailable. Progression was slow and after more
than 15 years, she remained ambulant with assistance at
age 53. Serum CK was mildly elevated at 370 U/L, and
there was no evidence of cardiac, respiratory, or non-
muscular neurological involvement. A first biopsy taken
from the left quadriceps was reported as normal. Subse-
quent biopsy of biceps tissue revealed pathology that was
strikingly focal; affected areas showed vacuoles with thin
basophilic rimming, as well as marked variation in fiber
size, rounded fibers, infiltration of endomysial tissue,
increased internalized nuclei, and abundant atrophic
fibers (Figure 2). On clinical histological examination,
cytoplasmic bodies were seen, though rarely, and the
vacuoles did not stain positive for amyloid by Congo red.
Three of the proband’s sisters were reported as
affected, with onset in their 30s, but additional clinical
information was unavailable. An affected brother pre-
sented at age 27 with inability to stand on tiptoe, fol-
lowed later by difficulty running and walking. His
progression was relatively rapid; by age 33 he began to
fall and lost ambulation, whereas his four affected sisters
remained ambulant with assistance at ages ranging from
39 to over 50. At the time of examination, the brother
had lost nearly all movement in his legs; his weakness
was too advanced to assess quadriceps sparing. He was
r a t e da s1 / 5f o rk n e ee x t e n s i o n ,k n e ef l e x i o n ,a n dh i p
flexion strength, and 0/5 for ankle dorsiflexion and ever-
sion. He could not stand from sitting and had severe
Figure 1 Pedigree. Subjects with DNA samples available and
tested are labeled with their identification number. Black-filled
symbols represent individuals affected with HIBM2, with onset in
their 20s or 30s. Tested patients were compound heterozygous with
genotype NM_005476.5: c.[1816+5G>A]+[2086G>A]. The gray-filled
symbol represents an individual presenting in his 70s with mild
HIBM-like symptoms, with genotype NM_005476.5: c.[1816+5G>A]
+[=]. Arrow indicates the proband.
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he developed weakness of his upper extremities that was
initially proximal but later distal, manifesting as weak
grip and difficulty writing. Electromyography was not
performed. Serum CK was mildly elevated at 420 U/L
(reference range 57-366), and there was no cardiac,
respiratory, or non-muscular neurological involvement.
For both the proband and her affected brother, the diag-
nosis was reported at different exams as either possible
limb girdle muscular dystrophy or a distal myopathy.
The proband reported both of her parents to be
asymptomatic, making the mode of inheritance appear
autosomal recessive, but later her father was noted to
exhibit slowness in walking and a shuffling gait. Upon
clinical evaluation, the mother of the proband was unaf-
fected, and the proband’s father (age 79 at exam) had
full strength in his upper extremities and proximal
lower limbs. However, his ankle dorsiflexion was
described as weak and rated as 4+/5, and he was unable
to heel-walk, indicating possible weakness of the tibialis
anterior muscles. He also had difficulty toe-walking. His
symptoms mimicked the pattern of weakness of his five
affected children, but were markedly less severe. The
age of onset of his symptoms was unknown.
Linkage scan and DNA sequence analysis
The parents of the proband originated from the same
region of India, but were not known to be related. The
proportion of homozygous and heterozygous genotypes
in their children, compared to children of known con-
sanguineous and non-consanguineous couples, sup-
ported the hypothesis that the parents were unrelated
(data not shown). A linkage scan under an autosomal
recessive model produced fourteen linkage peaks at or
near the maximum possible LOD score of 1.454. The
only known LGMD gene within any of these linkage
peaks was CAV3, in which mutations cause autosomal
dominant LGMD1C [13]. CAV3 was screened and no
mutations were found. A linkage peak on chromosome
9 contained three genes associated with different mus-
cle disorders: VCP, TPM2,a n dGNE. Mutations in
VCP and TPM2 were considered unlikely due to the
mode of inheritance, clinical presentation, or patholo-
gical characteristics of the associated diseases not
matching those of the family [14,15]. However, review
of the patients’ clinical and histological information
suggested their presentation was consistent with a
diagnosis of HIBM.
Sequence analysis of GNE revealed the proband was
heterozygous for both a novel mutation in the 5’ con-
sensus splice donor sequence of intron 10 (c.1816
+ 5 G > A )a n dak n o w nm i s s e n s em u t a t i o ni ne x o n1 2
(c.2086G>A, p.V696M), previously reported in families
of Indian and Thai origin [5,16-18]. The mutations seg-
regated according to the disease in all available family
members and were confirmed to be in trans; the father
was heterozygous for c.1816+5G>A, the mother was
heterozygous for c.2086G>A (p.V696M), all three avail-
able affected children were compound heterozygous for
both mutations, and the two unaffected children were
both heterozygous for one of the two mutations. The
novel c.1816+5G>A mutation was absent from 703
unrelated control subjects comprised of 446 of Middle
Eastern ancestry and 257 of miscellaneous European
ancestry. The c.1816+5G nucleotide was conserved in
18 of 20 vertebrate species examined; two species of
bird had a cytosine at that position (Additional file 1:
Supplemental Figure S1).
Figure 2 Pathology characteristic of HIBM in biceps muscle
biopsy from proband. A) Hematoxylin and eosin staining showed
marked variation in fiber diameter, rounded fibers, mild endomysial
fibrosis, slight fatty infiltration, and irregular vacuoles (arrows)
containing granular material. Frankly necrotic fibers, basophilic
regenerating fibers, and inflammatory infiltrates were not prominent.
The disease process appeared focal, with fibers in some areas mildly
affected, while other regions, including the one shown here,
exhibited severe myopathic pathology. B) Modified Gomori
trichrome staining highlighted small amounts of granular red
material within and around the vacuoles (arrow), as well as
endomysial fibrosis and small, angulated, atrophic fibers.
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myopathic symptoms and her brother was more severely
affected than his affected siblings, we sequenced the
gene N-acetylglucosamine kinase (NAGK)i nt h e s et w o
individuals to search for a potential modifier allele.
NAGK has been reported to be partially functionally
redundant with GNE kinase activity in some model sys-
tems [19-23]. However, there were no mutations in the
coding sequence or splice junctions in either subject.
Mutation characterization
An RT-PCR amplicon spanning exons 7 to 12 of the
GNE transcript showed two products in the proband
and her father, both of whom carried the c.1816+5G>A
splice site mutation, whereas the proband’sm o t h e ra n d
control samples showed only the expected full-length
band (Figure 3). Both bands were individually purified
and sequenced from the proband and her father, and in
both subjects the larger product was confirmed to repre-
sent the full-length amplicon, while the smaller product
lacked exon 10. Skipping of exon 10, comprised of 183
base pairs, at the mRNA level would result in an in-
frame deletion (p.G545_D605del) of 61 amino acids.
Both the p.G545_D605del and p.V696M mutations are
in the kinase domain of the GNE protein; mutations
throughout the gene, in both the epimerase and kinase
domains, can be pathogenic for HIBM2 [5].
Discussion
We report a family with five siblings affected with
HIBM2, which we diagnosed primarily by linkage analy-
sis and identification of mutations in GNE.R e c e n t l y ,w e
used a similar approach to achieve a molecular diagnosis
for a family with multiminicore disease, another rare
myopathy that can be mistaken for LGMD [24]. The
exclusion in our linkage scan of almost all known myo-
pathy genes [25], despite fourteen regions showing link-
age at a LOD score of approximately 1.4, confirms the
value of linkage analysis as a diagnostic tool even in
families not informative enough to generate suggestive
or significant LOD scores.
Several features of the clinical and pathological pre-
sentation of the family made the diagnosis initially
uncertain. First, the proband came to medical attention
prior to the identification of mutations in GNE as the
cause of HIBM, so genetic testing for HIBM was not
then available. Moreover, the symptoms were suggestive
of LGMD, and LGMD is much more prevalent than
HIBM [26-30]. HIBM is predominantly found among
Middle Eastern Jewish families [5,31] and Japanese
families (as DMRV/NM) [10,32]; it appears to be much
rarer among other populations [33]. Only a few previous
families of Asian Indian ancestry have been documented
with mutations in GNE [5,16]. Furthermore, an initial
biopsy of the quadriceps of the proband appeared nor-
mal, which in retrospect is consistent with a quadriceps-
sparing myopathy, but may have initially confounded
diagnosis. A later biopsy revealed the pathologic hall-
marks of HIBM; however, the characteristic rimmed
vacuoles are not specific to HIBM [2] and were negative
for amyloid by Congo red staining, which is atypical for
HIBM [34]. Finally, because five of seven siblings were
affected and their father appeared symptomatic, autoso-
mal dominant inheritance was plausible, provided that
the father’s much milder symptoms could be explained
by variable expressivity. Therefore, both dominant and
recessive muscular dystrophies and myopathies were
potential candidates.
Our linkage scans were performed under a recessive
model, and our identification of compound heterozy-
gous mutations in affected subjects confirmed this mode
of inheritance. However, the father (Subject 3) was het-
erozygous for the c.1816+5G>A splice site mutation,
and at age 79 he displayed slight weakness in his lower
extremities similar in its pattern to his affected children.
The predicted deletion of 61 amino acids (p.
G545_D605del) in the kinase domain of GNE would be
expected to result in an extremely hypomorphic or null
Figure 3 Correlation of GNE transcript length with c.1816+5G>A splice mutation genotype. RNA was extracted from muscle biopsy tissue
for subject 1159-1 and from saliva for subjects 1159-2 and 1159-3. By capillary electrophoresis, RT-PCR produced a single band of the expected
size in control samples and 1159-2, the mother of the proband, in whom the c.1816+5G>A mutation was absent. The proband (1159-1), and her
father (1159-3), both of whom were heterozygous for the c.1816+5G>A mutation, showed the full length band and a shorter band that lacked
exon 10.
Boyden et al. BMC Medical Genetics 2011, 12:87
http://www.biomedcentral.com/1471-2350/12/87
Page 4 of 7allele, and thus the weakness in Subject 3 could possibly
be a result of haploinsufficiency of GNE.M u t a t i o n s
showing incomplete dominance have been documented
for other recessive myopathies [35-37]. However, with-
out additional clinical examination and biopsy tissue we
could not determine if the symptoms in Subject 3 repre-
sented a milder version of HIBM or normal age-related
weakness. Alternatively, an unknown enhancer mutation
in a modifier gene, or an effect of gender on the mani-
festation of the splice mutation, could potentially
account for the myopathic symptoms in Subject 3 as
well as the faster deterioration of his affected son than
his four affected daughters.
The mechanism whereby mutations in GNE result in
muscle weakness is not completely understood [38].
Approximately 80 different mutations in GNE have been
previously reported [18,33,39-42], of which only two are
in splice sites. Like the c.1816+5G>A mutation
described herein, these mutations likely result in null
alleles [10,43]. The vast majority of mutations in GNE
are missense [33], and no patients have been recorded
as homozygous or compound heterozygous for two null
mutations, suggesting a complete loss of function of
GNE might be lethal in humans [5], as in mice [44].
Accordingly, the p.V696M mutation reported both here
and previously [5,16-18], often in conjunction with very
severe mutations, may be relatively benign, as otherwise
the patients might not retain enough residual GNE
activity to permit life.
Conclusions
We demonstrate the utility of genetic analyses as a diag-
nostic tool for heterogeneous disorders. In a family with
an undiagnosed distal myopathy, we excluded known
candidate genes by linkage analysis and identified com-
pound heterozygous mutations in GNE,w h i c h ,i nc o n -
junction with biopsy analysis, confirmed the diagnosis as
h e r e d i t a r yi n c l u s i o nb o d ym y o p a t h yt y p e2 .An o v e l
splice site mutation, c.1816+5G>A, resulted in skipping
of exon 10 and a predicted in-frame deletion in the
kinase domain of GNE, likely producing a null allele. A
c.1816+5G>A carrier showed mild and late-onset distal
weakness, so further study to evaluate the effect of par-
tial GNE function may be warranted. Our data contri-
bute to a more complete description of the clinical and
allelic heterogeneity of HIBM2, and may facilitate diag-
nosis in other unresolved cases.
Additional material
Additional file 1: Supplemental Figure S1. Evolutionary
conservation of the GNE:c.1816+5G nucleotide. DNA sequence
orthologous to human GNE exon 10 and intron 10 was aligned in 20
vertebrate species, of which 18 species shared the c.1816 + 5G
nucleotide. Two species of bird had a cytosine at that position. Box
indicates mutated nucleotide. Bold indicates exonic sequence. Asterisks
denote perfectly conserved positions.
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